Celergen Offers Relief from Rheumatoid Arthritis - Celergen Switzerland
 
Celergen Offers Relief from Rheumatoid Arthritis
Celergen
December 7, 2018

What is Rheumatoid Arthritis

Rheumatoid Arthritis is an autoimmune disease that causes joint pain and damage throughout the body. The symptoms are similar to other forms of arthritis which often might cause it to be misdiagnosed.

Symptoms traditionally include joint pain, joint swelling and/or stiffness and the less of joint function. The severity of the pain varies from case to case and like most ailments, the early diagnosis of it enables doctors to better treat it.

Man-with-Joint-Pain

Celergen on Rheumatoid Arthritis

Independent clinical trials conducted on Celergen have shown its tremendous efficacy in providing relief for patients with Rheumatoid Arthritis. In the study, patients showed an average reduction of a minimum of 30% in the number of swollen joints after just one month of use.

21% reported a complete relief from pain while 68.5% of participants mentioned that they felt significantly less pain as compared to before taking Celergen.

One of the reasons as to why Celergen is so effective in combating Rheumatoid Arthritis is because it contains Hydro MN Peptide, which consists of premium quality marine polypeptides of low molecular weights. These polypeptides of collagenic type have a similar composition of protein as cartilage. As such, Hydro MN peptide plays a key role in cartilage regeneration and reconstruction.

It is for this reason as to why many top Anti-Aging and Orthopedic doctors prescribe Celergen to their patients who are diagnosed with Rheumatoid Arthritis. The results speak for themselves.

dr-michael

MICHAEL KLENTZ

“No surgery. Celergen heals the tear on my left knee meniscus. Celergen really works wonders, by directly affecting the immune system, regenerating, rejuvenating, reducing inflammation and creating a more youthful looking, energetic personality.”

Comments

0 Comments

Your email address will not be published. Required fields are marked *

  1. No Comments